Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2017

07.12.2016 | Review

Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?

verfasst von: Magdalini Patseadou, Lina Michala

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective method of contraception, while also providing various non-contraceptive benefits. Although targeted primarily to adults, there is increasing experience in its use in adolescence. The aim of this review is to assess the available information on LNG-IUS usage in adolescence.

Methods

We conducted an online search on MEDLINE and SCOPUS from inception to May 24, 2015. All studies that examined LNG-IUS use in teen populations were eligible for inclusion. Primary outcome measures included description of indications for LNG-IUS usage and relevant efficacy. Secondary outcomes included complications, such as device-related problems (perforation and expulsion) and other adverse events (pelvic inflammatory disease, PID). Acceptability of the LNG-IUS was also estimated through evaluation of continuation rate and reasons for removal were assessed.

Results

Twenty-one studies met our inclusion criteria. We identified only one randomized controlled trial (RCT). All other twenty studies were observational. Pregnancy rates ranged from 0 to 2.7%. Management of heavy or/and painful periods was successful in 92–100%. Menstrual manipulation in patients with developmental delay was achieved in over 93% of cases. Expulsion rates ranged from 0 to 13% and pelvic infection/cervicitis between 0 and 2.7%. There were no reported uterine perforations.

Conclusion

Usage of the LNG-IUS in teen populations appears to be safe and efficacious both in terms of contraception and menstrual management. However, more robust evidence is needed so as to provide firm confirmation on benefits and potential side effects.
Literatur
2.
Zurück zum Zitat Jonsson B, Landgren B-M, Eneroth P (1991) Effects of various IUDs on the composition of cervical mucus. Contraception 43:447–458CrossRefPubMed Jonsson B, Landgren B-M, Eneroth P (1991) Effects of various IUDs on the composition of cervical mucus. Contraception 43:447–458CrossRefPubMed
3.
Zurück zum Zitat Jones RL, Critchley HO (2000) Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 15(Suppl. 3):162–172CrossRefPubMed Jones RL, Critchley HO (2000) Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 15(Suppl. 3):162–172CrossRefPubMed
4.
Zurück zum Zitat Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T (1986) Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 5:235–241CrossRefPubMed Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T (1986) Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 5:235–241CrossRefPubMed
6.
Zurück zum Zitat Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, Griesmacher A, Concin N, Concin H, Wildt L (2012) Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 86:345–349CrossRefPubMed Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, Griesmacher A, Concin N, Concin H, Wildt L (2012) Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 86:345–349CrossRefPubMed
7.
Zurück zum Zitat Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E (1990) Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 42:51–66CrossRefPubMed Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E (1990) Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 42:51–66CrossRefPubMed
8.
Zurück zum Zitat Zhu PD, Luo HZ, Xu RH, Cheng J, Wu SC, Chen JH, Wu MZ, Wang XP (1989) The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium—a comparative study of three IUDs. Contraception 40:425–438CrossRefPubMed Zhu PD, Luo HZ, Xu RH, Cheng J, Wu SC, Chen JH, Wu MZ, Wang XP (1989) The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium—a comparative study of three IUDs. Contraception 40:425–438CrossRefPubMed
9.
Zurück zum Zitat Hickey M, Crewe J, Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA (2006) Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab 91:3189–3198CrossRefPubMed Hickey M, Crewe J, Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA (2006) Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab 91:3189–3198CrossRefPubMed
10.
Zurück zum Zitat Luukkainen T, Lähteenmäki P, Toivonen J (1990) Levonorgestrel releasing intrauterine device. Ann Med 22:85–90CrossRefPubMed Luukkainen T, Lähteenmäki P, Toivonen J (1990) Levonorgestrel releasing intrauterine device. Ann Med 22:85–90CrossRefPubMed
11.
Zurück zum Zitat Robinson GE, Bounds W, Kubba AA, Adams J, Guillebaud J (1989) Functional ovarian cysts associated with the levonorgestrel releasing intrauterine device. Br J Fam Plann 14:131–132 Robinson GE, Bounds W, Kubba AA, Adams J, Guillebaud J (1989) Functional ovarian cysts associated with the levonorgestrel releasing intrauterine device. Br J Fam Plann 14:131–132
12.
Zurück zum Zitat American College of Obstetricians and Gynecologists Committee on Gynecologic Practice (2006) ACOG Committee Opinion. No337: Noncontraceptive uses of the levonorgestrel intrauterine system. Obstet Gynecol 107:1479–1482CrossRef American College of Obstetricians and Gynecologists Committee on Gynecologic Practice (2006) ACOG Committee Opinion. No337: Noncontraceptive uses of the levonorgestrel intrauterine system. Obstet Gynecol 107:1479–1482CrossRef
13.
Zurück zum Zitat World Health Organization (WHO) (2010) Medical Eligibility Criteria for Contraceptive Use-4th ed 2009. WHO, Geneva World Health Organization (WHO) (2010) Medical Eligibility Criteria for Contraceptive Use-4th ed 2009. WHO, Geneva
14.
Zurück zum Zitat Centers for Disease Control and Prevention (2010) US Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 59(RR-4):1–86 Centers for Disease Control and Prevention (2010) US Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 59(RR-4):1–86
15.
Zurück zum Zitat Faculty of Sexual and Reproductive Health Care (2009) The Royal College of Obstetricians and Gynecologists. UK Medical Eligibility Criteria for Contraceptive Use. Faculty of Sexual and Reproductive Health Care, London Faculty of Sexual and Reproductive Health Care (2009) The Royal College of Obstetricians and Gynecologists. UK Medical Eligibility Criteria for Contraceptive Use. Faculty of Sexual and Reproductive Health Care, London
16.
Zurück zum Zitat Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists (2012) Committee Opinion No539: adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 120:983–988CrossRef Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists (2012) Committee Opinion No539: adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 120:983–988CrossRef
17.
Zurück zum Zitat Committee on Adolescence, The American Pediatric Academy (2014) Contraception for Adolescents. Pediatrics 134:1244–1256CrossRef Committee on Adolescence, The American Pediatric Academy (2014) Contraception for Adolescents. Pediatrics 134:1244–1256CrossRef
18.
Zurück zum Zitat Lyus R, Lohr P, Prager S, Board of the Society of Family Planning (2010) Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81:367–371CrossRefPubMed Lyus R, Lohr P, Prager S, Board of the Society of Family Planning (2010) Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81:367–371CrossRefPubMed
19.
Zurück zum Zitat Caddy S, Yudin MH, Hakim J, Money DM, Infectious Disease Committee; Society of Obstetricians and Gynaecologists of Canada (2014) Best practices to minimize risk of infection with intrauterine device insertion. J Obstet Gynaecol Can 36:266–276CrossRefPubMed Caddy S, Yudin MH, Hakim J, Money DM, Infectious Disease Committee; Society of Obstetricians and Gynaecologists of Canada (2014) Best practices to minimize risk of infection with intrauterine device insertion. J Obstet Gynaecol Can 36:266–276CrossRefPubMed
20.
Zurück zum Zitat Faculty of Sexual and Reproductive Health Care Clinical Guidance. The Royal College of Obstetricians and Gynecologists (2010) Contraceptive Choices for Young People. Faculty of Sexual and Reproductive Health Care, London Faculty of Sexual and Reproductive Health Care Clinical Guidance. The Royal College of Obstetricians and Gynecologists (2010) Contraceptive Choices for Young People. Faculty of Sexual and Reproductive Health Care, London
22.
Zurück zum Zitat Sexual Health and Family Planning Australia (SH&FPA) (2013). Time for a Change: Increasing the Use of Long-Acting Reversible Contraceptive methods in Australia. SH&FPA Sexual Health and Family Planning Australia (SH&FPA) (2013). Time for a Change: Increasing the Use of Long-Acting Reversible Contraceptive methods in Australia. SH&FPA
23.
Zurück zum Zitat World Health Organization (2002) Adolescent friendly health services—an agenda for change. WHO, Geneva World Health Organization (2002) Adolescent friendly health services—an agenda for change. WHO, Geneva
24.
Zurück zum Zitat Berenson AB, Tan A, Hirth JM, Wilkinson GS (2013) Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gynecol 121:951–958CrossRefPubMedPubMedCentral Berenson AB, Tan A, Hirth JM, Wilkinson GS (2013) Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gynecol 121:951–958CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM (2012) Continuation of reversible contraception in teenagers and young women. Obstet Gynecol 120:1298–1305CrossRefPubMedPubMedCentral Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM (2012) Continuation of reversible contraception in teenagers and young women. Obstet Gynecol 120:1298–1305CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Amies Oelschlager AM, Micks EA, Debiec KE, Nizamic T, Mantrala MD, Prager SW (2014) Long acting reversible contraception in adolescents with cardiovascular conditions. J Pediatr Adolesc Gynecol 27:353–355CrossRefPubMed Amies Oelschlager AM, Micks EA, Debiec KE, Nizamic T, Mantrala MD, Prager SW (2014) Long acting reversible contraception in adolescents with cardiovascular conditions. J Pediatr Adolesc Gynecol 27:353–355CrossRefPubMed
27.
Zurück zum Zitat Hillman JB, Miller RJ, Inge TH (2011) Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt) 20:533–538CrossRef Hillman JB, Miller RJ, Inge TH (2011) Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt) 20:533–538CrossRef
28.
Zurück zum Zitat Godfrey EM, Memmel LM, Neustadt A, Shah M, Nicosia A, Moorthie M, Gilliam M (2010) Intrauterine contraception for adolescents aged 14–18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T380A. Contraception 81:123–127CrossRefPubMed Godfrey EM, Memmel LM, Neustadt A, Shah M, Nicosia A, Moorthie M, Gilliam M (2010) Intrauterine contraception for adolescents aged 14–18 years: a multicenter randomized pilot study of levonorgestrel-releasing intrauterine system compared to the Copper T380A. Contraception 81:123–127CrossRefPubMed
29.
Zurück zum Zitat Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V (2014) Effects of age, parity and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 123:585–592CrossRefPubMed Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V (2014) Effects of age, parity and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 123:585–592CrossRefPubMed
30.
Zurück zum Zitat Behringer T, Reevers MF, Rossiter B, Chen BA, Schwarz EB (2011) Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception 84:e5–e10CrossRefPubMedPubMedCentral Behringer T, Reevers MF, Rossiter B, Chen BA, Schwarz EB (2011) Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception 84:e5–e10CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Teal SB, Sheeder J (2012) IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception 85:270–274CrossRefPubMed Teal SB, Sheeder J (2012) IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception 85:270–274CrossRefPubMed
32.
Zurück zum Zitat Howard DL, Wayman R, Strickland JL (2013) Satisfaction with and intention to continue Depo-Provera versus the Mirena IUD among post-partum adolescents through 12 months of follow-up. J Pediatr Adolesc Gynecol 26:358–365CrossRefPubMed Howard DL, Wayman R, Strickland JL (2013) Satisfaction with and intention to continue Depo-Provera versus the Mirena IUD among post-partum adolescents through 12 months of follow-up. J Pediatr Adolesc Gynecol 26:358–365CrossRefPubMed
33.
Zurück zum Zitat Paterson H, Ashton J, Harrison-Woolrych M (2009) A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception 79:433–438CrossRefPubMed Paterson H, Ashton J, Harrison-Woolrych M (2009) A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception 79:433–438CrossRefPubMed
34.
Zurück zum Zitat Chi C, Pollard D, Tuddenham EG, Kadir RA (2010) Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 23:215–222CrossRefPubMed Chi C, Pollard D, Tuddenham EG, Kadir RA (2010) Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 23:215–222CrossRefPubMed
35.
Zurück zum Zitat Silva CD, Geraldes F, Silva IS (2013) Levonorgestrel intrauterine system as a treatment option for severe menorrhagia in adolescent with type III von Willebrand disease. BMJ Case Rep. doi:10.1136/bcr-2013-008833 Silva CD, Geraldes F, Silva IS (2013) Levonorgestrel intrauterine system as a treatment option for severe menorrhagia in adolescent with type III von Willebrand disease. BMJ Case Rep. doi:10.​1136/​bcr-2013-008833
36.
Zurück zum Zitat Yoost J, LaJoie AS, Hertweck P, Loveless M (2013) Use of the levonorgestrel intrauterine system in adolescents with endometriosis. J Pediatr Adolesc Gynecol 26:120–124CrossRefPubMed Yoost J, LaJoie AS, Hertweck P, Loveless M (2013) Use of the levonorgestrel intrauterine system in adolescents with endometriosis. J Pediatr Adolesc Gynecol 26:120–124CrossRefPubMed
37.
Zurück zum Zitat Al-Jefout M, Palmer J, Fraser IS (2007) Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating endometriosis. Aust N Z J Obstet Gynaecol 47:247–249CrossRefPubMed Al-Jefout M, Palmer J, Fraser IS (2007) Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating endometriosis. Aust N Z J Obstet Gynaecol 47:247–249CrossRefPubMed
38.
Zurück zum Zitat Williamson M, Bulmer P (2010) Using the Mirena intrauterine system to treat severe primary dysmenorrhoea in an adolescent. J Obstet Gynaecol 30:206–207CrossRefPubMed Williamson M, Bulmer P (2010) Using the Mirena intrauterine system to treat severe primary dysmenorrhoea in an adolescent. J Obstet Gynaecol 30:206–207CrossRefPubMed
39.
Zurück zum Zitat Aslam N, Blunt S, Latthe P (2010) Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. J Obstet Gynaecol 30:489–491CrossRefPubMed Aslam N, Blunt S, Latthe P (2010) Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. J Obstet Gynaecol 30:489–491CrossRefPubMed
40.
Zurück zum Zitat Pillai M, O’Brien K, Hill E (2010) The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning diabilities. BJOG 117:216–221CrossRefPubMed Pillai M, O’Brien K, Hill E (2010) The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning diabilities. BJOG 117:216–221CrossRefPubMed
41.
Zurück zum Zitat Savasi I, Jayasinghe K, Moore P, Jayasinghe Y, Grover SR (2014) Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities. J Pediatr Adolesc Gynecol 27:25–28CrossRefPubMed Savasi I, Jayasinghe K, Moore P, Jayasinghe Y, Grover SR (2014) Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities. J Pediatr Adolesc Gynecol 27:25–28CrossRefPubMed
42.
Zurück zum Zitat Hillard PJ (2012) Menstrual suppression with the levonorgestrel intrauterine system in girls with developmental delay. J Pediatr Adolec Gynecol 25:308–313CrossRef Hillard PJ (2012) Menstrual suppression with the levonorgestrel intrauterine system in girls with developmental delay. J Pediatr Adolec Gynecol 25:308–313CrossRef
43.
Zurück zum Zitat Kirkham YA, Allen L, Kives S, Caccia N, Spitzer RF, Omstein MP (2013) Trends in menstrual concerns and suppression in adolescents with developmental disabilities. J Adolesc Health 53:407–412CrossRefPubMed Kirkham YA, Allen L, Kives S, Caccia N, Spitzer RF, Omstein MP (2013) Trends in menstrual concerns and suppression in adolescents with developmental disabilities. J Adolesc Health 53:407–412CrossRefPubMed
44.
Zurück zum Zitat Brown AJ, Westin SN, Broaddus RR, Schmeler K (2012) Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 119(2 Pt 2):423–426CrossRefPubMedPubMedCentral Brown AJ, Westin SN, Broaddus RR, Schmeler K (2012) Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 119(2 Pt 2):423–426CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Peipert JF, Madden T, Allsworth JE, Secura GM (2012) Preventing unintended preg-nancies by providing no-cost contraception. Obstet Gynecol 120:1291–1297CrossRefPubMedPubMedCentral Peipert JF, Madden T, Allsworth JE, Secura GM (2012) Preventing unintended preg-nancies by providing no-cost contraception. Obstet Gynecol 120:1291–1297CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF (2011) Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 84:493–498CrossRefPubMedPubMedCentral Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF (2011) Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 84:493–498CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Friedman JO (2015) Factors associated with contraceptive satisfaction in adolescent women using the IUD. J Pediatr Adolesc Gynecol 28:38–42CrossRefPubMed Friedman JO (2015) Factors associated with contraceptive satisfaction in adolescent women using the IUD. J Pediatr Adolesc Gynecol 28:38–42CrossRefPubMed
48.
Zurück zum Zitat Williams CE, Creighton SM (2012) Menstrual disorders in adolescents: review of current practice. Horm Res Paediatr 78:135–143CrossRefPubMed Williams CE, Creighton SM (2012) Menstrual disorders in adolescents: review of current practice. Horm Res Paediatr 78:135–143CrossRefPubMed
49.
Zurück zum Zitat Arruda MS, Petta CA, Abrao MS, Benetti-Pinto CL (2003) Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. Hum Reprod 18:4–9CrossRef Arruda MS, Petta CA, Abrao MS, Benetti-Pinto CL (2003) Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. Hum Reprod 18:4–9CrossRef
50.
Zurück zum Zitat American College of Obstetricians and Gynecologists (2005) ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol 105:921CrossRef American College of Obstetricians and Gynecologists (2005) ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol 105:921CrossRef
51.
Zurück zum Zitat Laufer MR, Goitein L, Bush M, Cramer DW, Emans SJ (1997) Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 10:199CrossRefPubMed Laufer MR, Goitein L, Bush M, Cramer DW, Emans SJ (1997) Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 10:199CrossRefPubMed
52.
Zurück zum Zitat Tharinger D, Horton CB, Millea S (1990) Sexual abuse and exploitation of children and adults with mental retardation and other handicaps. Child Abuse Negl 14:301CrossRefPubMed Tharinger D, Horton CB, Millea S (1990) Sexual abuse and exploitation of children and adults with mental retardation and other handicaps. Child Abuse Negl 14:301CrossRefPubMed
53.
Zurück zum Zitat Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM (2006) Depot medroxyprogesterone acetate and bone mineral density in adolescents—the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 39:296–301CrossRefPubMed Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM (2006) Depot medroxyprogesterone acetate and bone mineral density in adolescents—the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 39:296–301CrossRefPubMed
54.
Zurück zum Zitat Isley MM, Kaunitz AM (2011) Update on hormonal contraception and bone density. Rev Endocr Metab Disord 12:93CrossRefPubMed Isley MM, Kaunitz AM (2011) Update on hormonal contraception and bone density. Rev Endocr Metab Disord 12:93CrossRefPubMed
55.
Zurück zum Zitat American College of Obstetricians and Gynecologists Committee on Adolescent Health Care (2009) ACOG Committee Opinion no. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 114:1428CrossRef American College of Obstetricians and Gynecologists Committee on Adolescent Health Care (2009) ACOG Committee Opinion no. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 114:1428CrossRef
56.
Zurück zum Zitat Atkinson E, Bennett MJ, Dudley J, Grover S, Matthews K, Moore P, Quinlivan J, Walters T, Australian Society of Paediatric and Adolescent Gynaecology Working Party (2003) Consensus statement: Menstrual and contraceptive management in women with an intellectual disability. Aust N Z J Obstet Gynaecol 43:109CrossRefPubMed Atkinson E, Bennett MJ, Dudley J, Grover S, Matthews K, Moore P, Quinlivan J, Walters T, Australian Society of Paediatric and Adolescent Gynaecology Working Party (2003) Consensus statement: Menstrual and contraceptive management in women with an intellectual disability. Aust N Z J Obstet Gynaecol 43:109CrossRefPubMed
57.
Zurück zum Zitat Gadelha Da Costa A, Filho FM, Ferreira AC, Spara P, Mauad FM (2004) Uterine volume in adolescents. Ultrasound Med Biol 30:7–10CrossRefPubMed Gadelha Da Costa A, Filho FM, Ferreira AC, Spara P, Mauad FM (2004) Uterine volume in adolescents. Ultrasound Med Biol 30:7–10CrossRefPubMed
58.
Zurück zum Zitat Holm K, Laursen EM, Brocks V, Müller J (1995) Pubertal maturation of internal genitalia: an ultrasound evaluation of 166 healthy girls. Ultrasound Obstet Gynecol 6:175–181CrossRefPubMed Holm K, Laursen EM, Brocks V, Müller J (1995) Pubertal maturation of internal genitalia: an ultrasound evaluation of 166 healthy girls. Ultrasound Obstet Gynecol 6:175–181CrossRefPubMed
59.
Zurück zum Zitat Kamal I, Hefnawi F, Ghonheim M, Talant M, Abdalla M (1971) Dimensional and architectural disproportion between the intrauterine device and the uterine cavity: a cause of bleeding. Fert Steril 22:514–521CrossRef Kamal I, Hefnawi F, Ghonheim M, Talant M, Abdalla M (1971) Dimensional and architectural disproportion between the intrauterine device and the uterine cavity: a cause of bleeding. Fert Steril 22:514–521CrossRef
60.
Zurück zum Zitat Bayer LL, Jensen JT, Li H, Nichols MD, Bednarek PH (2012) Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. Contraception 86:443–451CrossRefPubMed Bayer LL, Jensen JT, Li H, Nichols MD, Bednarek PH (2012) Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. Contraception 86:443–451CrossRefPubMed
61.
Zurück zum Zitat Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O (1992) Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339:785–788CrossRefPubMed Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O (1992) Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339:785–788CrossRefPubMed
62.
Zurück zum Zitat Walsh T, Grimes D, Frezieres R, Nelson A, Bernstein L, Coulson A, Bernstein G (1998) Randomized controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 351:1005–1008CrossRefPubMed Walsh T, Grimes D, Frezieres R, Nelson A, Bernstein L, Coulson A, Bernstein G (1998) Randomized controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 351:1005–1008CrossRefPubMed
63.
Zurück zum Zitat ACOG Practice Bulletin No. 121 (2011) Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 118:184–196CrossRef ACOG Practice Bulletin No. 121 (2011) Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 118:184–196CrossRef
64.
Zurück zum Zitat Toivonen J, Luukkainen T, Allonen H (1991) Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 77:261–264CrossRefPubMed Toivonen J, Luukkainen T, Allonen H (1991) Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 77:261–264CrossRefPubMed
65.
Zurück zum Zitat Blanc AK, Tsui AO, Croft TN, Trevitt JL (2009) Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. International perspectives on sexual and reproductive health. Int Perspect Sex Reprod Health, p 63–71 Blanc AK, Tsui AO, Croft TN, Trevitt JL (2009) Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. International perspectives on sexual and reproductive health. Int Perspect Sex Reprod Health, p 63–71
Metadaten
Titel
Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?
verfasst von
Magdalini Patseadou
Lina Michala
Publikationsdatum
07.12.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2017
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-016-4261-0

Weitere Artikel der Ausgabe 3/2017

Archives of Gynecology and Obstetrics 3/2017 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.